Browsing by Author "Yorgancioğlu A."
Now showing 1 - 13 of 13
Results Per Page
Sort Options
Item Koah ve astımda atak; [KOAH ve astımda atak](Ankara University, 2015) Yildirim N.; Demir T.; Gemicioğlu B.; Kiyan E.; Oğuzülgen K.; Polatli M.; Saryal S.; Sayiner A.; Yorgancioğlu A.; Bavbek S.; Çelik G.E.; Günen H.; Mungan D.; Şen E.; Türktaş H.; Yildiz F.Chronic obstructive pulmonary disease (COPD) and asthma are airway diseases with acute exacerbations. Natural course of both disease are affected by exacerbations. COPD exacerbations may be caused by infections and other causes; indoor and outdoor pollution, cardiovascular diseases, asthma-COPD overlap syndrome, COPD- obstructive sleep apnea syndrome, pulmonary embolism, gastro-oesophageal reflux, anxiety-depression, pulmonary hypertension. Exposure to triggering factors, viral infections, treatment insufficiency may cause asthma exacerbations. Smoking cessations, prevention of infections, long-acting anticholinergics, long-acting β2 agonists, inhaled corticosteroids, phosphodiesterase-4 inhibitors, mucolytics, prophilactic antibiotics can be effective on the prevention of COPD exacerbations. Asthma exacerbations may be decreased by the avoidance of allergens, viral infections, occupational exposures, airpollution, treatment of comorbid diseases. Effective treatment of asthma is required to prevent asthma exacerbations. Inhaled steroids and combined treatments are the most effective preventive therapy for exacerbations. Patient education and cooperation is an element of the preventive measures for asthma attacks. Compliance to therapy, inhalation techniques, written asthma plans are required. The essential of COPD and asthma exacerbation treatment is bronchodilator therapy. Steroids are also implemented to the therapy, targeting the inflammation. Specific treatments of the cause (infection, airpollution, pulmonary embolism etc.) should be administered. © 2015, Ankara University. All rights reserved.Item Asthma-KOAH overlap syndrome; [Astım-KOAH overlap sendromu](Ankara University, 2015) Şen E.; Oğuzülgen K.; Bavbek S.; Günen H.; Kiyan E.; Türktaş H.; Yorgancioğlu A.; Polatli M.; Yildiz F.; Çelik G.; Demir T.; Gemicioğlu B.; Mungan D.; Saryal S.; Sayiner A.; Yildirim N.Asthma and chronic obstructive pulmonary disease (COPD) are common lung diseases characterized by chronic airway inflammation and airway obstruction. Among patient with COPD and asthma; there is a group of patients with an overlap between clinical, functional characteristics and airway inflammation patterns, named “Asthma-COPD Overlap Syndrome” (ACOS). ACOS is a syndrome characterized by reversible but persistant airflow limitation (postbronchodilator FEV1/FVC < 70%) which has some features of both asthma and COPD. ACOS should be suspected in a patient > 40 years, with smoking history, previous asthma diagnosis or history of childhood asthma who has persistant airflow limitation and reversible ariway obstruction (defined by an increase of > %12 of FEV1 pred or increase of FEV1 > 200 mL after inhalation of 400 mcg salbutamol or 1000 mcg terbutaline). The prevalence for ACOS has been reported 11-55% in different case series to date and increases by age and is more frequent in females in different age groups. Patients with ACOS are younger than COPD patients and older than asthma patients. Frequent and severe exacerbations and related hospitalization and emergency room visits are common in ACOS and this causes an impaired quality of life. Current recommendations of guidelines for pharmacologic treatment of ACOS have been composed of a combination with optimal COPD and asthma treatment. Future therapeutic approaches should be based on endotypes. Clinical phenotype and underlying endotype driven clinical studies may be the base of ACOS guidelines. © 2015, Ankara University. All rights reserved.Item Global Asthma Network survey suggests more national asthma strategies could reduce burden of asthma(Elsevier Doyma, 2017) Asher I.; Haahtela T.; Selroos O.; Ellwood P.; Ellwood E.; Billo N.E.; Bissell K.; Chiang C.-Y.; El Sony A.; García-Marcos L.; Mallol J.; Marks G.B.; Pearce N.; Strachan D.; Priftanji A.; Benhabylès B.; Boukari R.; Castracane F.A.; Gómez M.; Salmun N.; Baghdasaryan A.; Burgess S.; Mattes J.; Tai A.; Haidinger G.; Riedler J.; Shpakou A.; Weyler J.; Gninafon M.; Aguirre de Abruzzese J.; Domuz S.; Brandão H.V.; Camargos P.A.M.; de Britto M.; Fischer G.B.; Kuschnir F.C.; Menezes A.M.; Porto Neto A.C.; Rosário N.; Solé D.; Wandalsen N.F.; Mustakov T.B.; Birba E.; Mbatchou Ngahane B.H.; Pefura Yone E.W.; Rennie D.C.; To T.; Standring P.; Calvo Gil M.A.; Chen Y.-Z.; Kan X.; Lin Y.; Garcia E.; Niederbacher J.; Ordoñez G.A.; Kabengele Obel B.; Soto-Quirós M.E.; Banac S.; Yiallouros P.; Lochte L.; Barba S.; Cooper P.; El Falaki M.; Mokhtar A.; Figueroa Colorado M.; Berihu A.; Weihe P.; Lal V.A.; Mäkelä M.; Annesi-Maesano I.; Charpin D.; Raherison C.; Gotua M.; von Mutius E.; Addo-Yobo E.O.; Clement N.F.; Gratziou C.; Tsanakas J.; Akpinar-Elci M.; Lai C.K.W.; Novák Z.; Awasthi S.; Ilangho R.; Maitra A.; Mukherjee M.; Pai U.A.; Pherwani A.V.; Reddy B.K.; Sabir M.; Sharma S.K.; Singh V.; Singh M.; Sukumaran T.U.; Varkki S.; Kartasasmita C.B.; Cheraghi M.; Karimi M.; Masjedi M.-R.; Manning P.; Shohat T.; Bonini S.; Forastiere F.; La Grutta S.; Petronio M.G.; Piffer S.; Kahwa E.; Odajima H.; Yoshihara S.; Abu-Ekteish F.; Al Omari O.; Amukoye E.I.; Esamai F.O.; Hong S.-J.; Neziri-Ahmetaj L.; Al-Momen J.A.; Svabe V.; Shenkada M.; Vlaski E.; Mortimer K.; de Bruyne J.; Toloba Y.; Montefort S.; Del-Río-navarro B.E.; García-Almaráz R.; González-Díaz S.N.; Hernández-Colín D.D.; Jiménez González C.A.; Mérida-Palacio J.V.; Brunekreef B.; Currie S.; Douwes J.; Graham D.; Hancox R.; Moyes C.; Pattemore P.; Cordero Rizo M.Z.; Erhabor G.E.; Falade A.; Garba Ilah B.; Hammangabdo A.; Onyia N.; Pulu M.; Nystad W.; Al-Rawas O.; Yusuf M.O.; Watson B.M.; El Sharif N.; Cukier G.; Checkley W.; Chiarella P.; Pagcatipunan R.; Lis G.; Morais-Almeida M.; Deleanu D.; Kamaltynova E.; Kondiurina E.G.; Esera-Tulifau L.; Al-Ghamdi B.R.; Yousef A.; Toure N.O.; Hadnadjev M.; Višnjevac D.; Zivkovic Z.; Fadlu-Deen G.; Goh D.Y.T.; Masekala R.; Voyi K.; Zar H.J.; Arnedo-Pena A.; Busquets R.M.; Carvajal-Urueña I.; González Díaz C.; Korta Murua J.; López-Silvarrey Varela A.; Luna-Paredes C.; Morales-Suárez-varela M.; Praena-Crespo M.; Rabadán-Asensio A.; Wärnberg J.; Gunasekera K.D.; Kudagammana S.T.; Hassanain S.; Mohammad Y.; Guo Y.L.; Huang J.-L.; Laoaraya M.; Phumethum S.; Teeratakulpisarn J.; Vichyanond P.; Anderson S.; Tidjani O.; Iosefa T.; Aho G.; Dookeeram D.; Hamzaoui A.; Yorgancioğlu A.; Ituaso-Conway N.; Worodria W.; Fedortsiv O.; Mahboub B.; Mansur A.H.; Doshi R.P.; Redding G.J.; Yeatts K.; Valentin-Rostan M.; Harrison G.; Le L.T.T.; Wa Somwe S.; Manangazira P.Background Several countries or regions within countries have an effective national asthma strategy resulting in a reduction of the large burden of asthma to individuals and society. There has been no systematic appraisal of the extent of national asthma strategies in the world. Methods The Global Asthma Network (GAN) undertook an email survey of 276 Principal Investigators of GAN centres in 120 countries, in 2013–2014. One of the questions was: “Has a national asthma strategy been developed in your country for the next five years? For children? For adults?”. Results Investigators in 112 (93.3%) countries answered this question. Of these, 26 (23.2%) reported having a national asthma strategy for children and 24 (21.4%) for adults; 22 (19.6%) countries had a strategy for both children and adults; 28 (25%) had a strategy for at least one age group. In countries with a high prevalence of current wheeze, strategies were significantly more common than in low prevalence countries (11/13 (85%) and 7/31 (22.6%) respectively, p < 0.001). Interpretation In 25% countries a national asthma strategy was reported. A large reduction in the global burden of asthma could be potentially achieved if more countries had an effective asthma strategy. © 2017 SEICAPItem Asthma in the context of global alliance against respiratory diseases (GARD) in Turkey(AME Publishing Company, 2018) Yorgancioğlu A.; Gemicioglu B.; Ekinci B.; özkan Z.; Bayram H.; Ergan B.; Ersu R.; Kocabaş A.; Köktürk N.[No abstract available]Item The global burden of chronic airway diseases(Elsevier, 2018) Yorgancioğlu A.Hundreds of millions of people of all ages and in all countries of the world are affected by preventable chronic respiratory diseases (CRDs). More than 50% of them live in low- and middle-income countries or deprived populations. A program within the World Health Organization (WHO) as Global Alliance against chronic respiratory diseases (GARD) has begun in 2005, with the aim of raising the recognition of the importance of CRDs as one of the most important health problems globally. GARD member countries develop activities against CRDs, which are conducted by their governments and supported by GARD when requested by the national health authorities. Activities have been initiated in more than 30 GARD countries in the areas of surveillance, prevention, management, and advocacy. GARD country projects vary in different countries according to the country-specific needs and the level of engagement of governmental health departments. This chapter evaluates the activities of GARD around the world and emphasizes over the gaps that are needed to be filled. © 2018 Elsevier Inc. All rights reserved.Item The validity and reliability of the turkish version of the leicester cough questionnaire in COPD patients(Turkiye Klinikleri Journal of Medical Sciences, 2018) Kurhan F.; Göktalay T.; Havlucu Y.; Sari S.; Yorgancioğlu A.; Çelik P.; Şakar Coşkun A.Background/aim: The reliability and validity of the Turkish version of the Leicester Cough Questionnaire (LCQ) have been evaluated before. This study aimed to validate the Turkish version of the LCQ in chronic obstructive pulmonary disease (COPD) patients with cough. Materials and methods: COPD (GOLD B, C, D) patients over age 40 (n = 75) and healthy volunteers as a control group (n = 75) were included. A sociodemographic data form, the LCQ, the Short Form-36 (SF-36) quality of life questionnaire, and the World Health Organization Quality of Life Brief Form for Turkish people were completed. The internal reliability of the LCQ was determined using the Cronbach alpha coefficient (>0.6) and its repeatability by the intraclass consistency coefficient (P < 0.05) was accepted as significant. Results: For internal consistency, Cronbach alpha coefficients of all subscales of the LCQ, physical, psychological, and social, were found as 0.72, 0.86, and 0.83, respectively, with 0.92 for the total index. There was significant internal consistency for all subscales and the total index (Cronbach alpha coefficients of >0.6). In test–retest reliability, the correlation coefficient ranged between 0.71 and 0.80 for each question and was calculated as r = 0.89 for total LCQ score (P < 0.001). Conclusion: The Turkish version of the LCQ has been found to have acceptable reliability and validity for use in Turkish COPD patients with chronic cough. © TÜBİTAK.Item Does rhinitis pharmacotherapy improve control of comorbid asthma?(Springer International Publishing, 2020) Şenel F.Ç.; Yorgancioğlu A.; Cruz A.A.Asthma is a disorder usually characterised by chronic inflammation of the airway mucosa of the bronchi and also the more distal airways, featuring a varying (and often remediable) degree of airflow limitation, hyperreactivity of the bronchi and periodic flare-ups, in which respiratory difficulties, such as wheeze, cough with sputum, shortness of breath and a tight chest, are the most common symptoms. AR, which may occur together with conjunctivitis, affects the supralaryngeal portion of the airways and is triggered by the nasal epithelium coming into contact with allergens, thus provoking an inflammatory response initiated by specific IgE. Patients complain of nasal discharge, pruritus, sneeze and blockage of the nose. There is a similar inflammatory pattern in both regions of the airway, if AR or asthma is chronic or when allergens are deliberately presented to the airway mucosa in a provocation test. In both conditions, there are indications of a systemic inflammatory response that may lead to eosinophilic inflammation of the entire airways. Asthma and AR are frequently found together, and AR is a strong predictor for asthma. The fact that asthma and AR can both be treated in similar fashion is also suggestive of a close similarity between the two conditions. Guidelines for management pay attention to this connection and advise assessing patients presenting with asthma for AR and vice versa. Pharmacotherapy should aim to treat both disorders simultaneously for maximum control and to reduce the number of agents needed for treatment. It is plausible that treatment guidelines may eventually suggest a goal of managing the entire respiratory system at once. Such a development would pave the way for a fully inclusive view of personalised holistic management of both the upper and lower airway. © Springer Nature Switzerland AG 2021.Item Protocol for the earco registry: A pan-european observational study in patients with α1-antitrypsin deficiency(European Respiratory Society, 2020) Greulich T.; Altraja A.; Barrecheguren M.; Bals R.; Chlumsky J.; Chorostowska-Wynimko J.; Clarenbach C.; Corda L.; Corsico A.G.; Ferrarotti I.; Esquinas C.; Gouder C.; Hećimović A.; Ilic A.; Ivanov Y.; Janciauskiene S.; Janssens W.; Kohler M.; Krams A.; Lara B.; Mahadeva R.; McElvaney G.; Mornex J.-F.; O’hara K.; Parr D.; Piitulainen E.; Schmid-Scherzer K.; Seersholm N.; Stockley R.A.; Stolk J.; Sucena M.; Tanash H.; Turner A.; Ulmeanu R.; Wilkens M.; Yorgancioğlu A.; Zaharie A.; Miravitlles M.Rationale and objectives: Alpha-1 antitrypsin deficiency (AATD) is a genetic condition that leads to an increased risk of emphysema and liver disease. Despite extensive investigation, there remain unanswered questions concerning the natural history, pathophysiology, genetics and the prognosis of the lung disease in association with AATD. The European Alpha-1 Clinical Research Collaboration (EARCO) is designed to bring together researchers from European countries and to create a standardised database for the follow-up of patients with AATD. Study design and population: The EARCO Registry is a non-interventional, multicentre, pan-European, longitudinal observational cohort study enrolling patients with AATD. Data will be collected prospectively without interference/modification of patient’s management by the study team. The major inclusion criterion is diagnosed severe AATD, defined by an AAT serum level <11 µM (50 mg·dL−1 ) and/or a proteinase inhibitor genotype ZZ, SZ or compound heterozygotes or homozygotes of other rare deficient variants. Assessments at baseline and during the yearly follow-up visits include lung function testing (spirometry, body plethysmography and diffusing capacity of the lung), exercise capacity, blood tests and questionnaires (symptoms, quality of life and physical activity). To ensure correct data collection, there will be designated investigator staff to document the data in the case report form. All data will be reviewed by the EARCO database manager. Summary: The EARCO Registry aims to understand the natural history and prognosis of AATD better with the goal to create and validate prognostic tools to support medical decision-making. © ERS 2020.Item Country-based report: The safety of omalizumab treatment in pregnant patients with asthma(Turkiye Klinikleri, 2021) Gemicioğlu B.; Yalçin A.D.; Havlucu Y.; Karakaya G.; Özdemir L.; Keren M.; Bavbek S.; Ediger D.; Oğuzülgen İ.K.; Özşeker Z.F.; Yorgancioğlu A.Background/aim: We aimed to report outcomes of pregnant patients with asthma under omalizumab treatment and their infants in our country. Materials and methods: Patients with asthma who received omalizumab for at least 6 months and at least one dose during their pregnancy were retrospectively evaluated using a questionnaire regarding their disease and therapy and the health of their infants. Results: Twenty pregnant patients and their 23 infant’s data were analyzed. The mean delivery age was 31.8 ± 7.4 years. They received omalizumab for 28.9 ± 21.8 months. Eight (36.4%) patients showed exacerbation of the disease during pregnancy. Forced expiratory volume in 1 s (FEV1) and asthma control test (ACT) scores at the starting time of omalizumab administration, first month of the pregnancy, and after delivery were 71 ± 18%, 83.4 ± 10.5%, and 80.5 ± 13% (FEV1), and 11.9 ± 4.9, 20.2 ± 2.6, and 20.4 ± 2.2 (ACT), respectively. One patient gave birth to twin infants, two patients to two infants each in different years, and 17 to one infant each. Three (13%) infants had low birth weight and five (21.7%) were born prematurely. No congenital anomalies were detected. Seven (30.4%) infants presented atopic diseases during their life. Conclusion: Omalizumab treatment during pregnancy seems to be safe for both patients and their infants. © TÜBİTAK.Item Treatment of respiratory infections in pregnant patients: Overview(Springer International Publishing, 2022) Başlilar S.; Kocakaya D.; Yorgancioğlu A.It is reported that antibiotics represent almost 80% of the drugs prescribed to pregnant women and that between 1 in 5 and 1 in 4 pregnant women are administered antibiotic pharmacotherapy [1-3]. In pregnant women, the most frequently occurring infections are urinary tract infections (UTIs) (cystitis and pyelonephritis), venereal infections and the upper respiratory tract infections (URTIs) [1]. © The Author(s), under exclusive license to Springer Nature Switzerland AG 2022.Item Important steps towards a big change for lung health: a joint approach by the European Respiratory Society, the European Society of Radiology and their partners to facilitate implementation of the European Union’s new recommendations on lung cancer screening(European Respiratory Society, 2023) Ward B.; Vašáková M.K.; Cordeiro C.R.; Yorgancioğlu A.; Chorostowska-Wynimko J.; Blum T.G.; Kauczor H.-U.; Samarzija M.; Henschke C.; Wheelock C.; Grigg J.; Andersen Z.J.; Koblížek V.; Májek O.; Odemyr M.; Powell P.; Seijo L.M.[No abstract available]Item Asthma-chronic obstructive pulmonary disease overlap: Results from a national-multicenter study; [Astım KOAH overlap: Ulusal çok merkezli bir çalışma sonuçları](Ankara University, 2024) Çelik G.E.; Aydin Ö.; Şen E.; Demir T.; Gemicioğlu B.; Kiyan E.; Mungan D.; Kivilcim Oğuzülgen İ.; Polatli M.; Göksel Ö.; Sayiner A.; Yildirim N.; Yildiz F.; Yorgancioğlu A.; Elhan A.H.; Yildiz Ö.; Başyiğit İ.; Börekçi Ş.; Havlucu Y.; Okumuş G.; Türk M.; Saryal S.Introduction: Patients with asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO) have a greater disease burden than those with COPD or asthma alone. In this study, it was aimed to determine the prevalence, risk factors, and clinical features of ACO because there are limited national data in Türkiye. Materials and Methods: The study was conducted in a cross-sectional design in nine tertiary-care hospitals. The patients followed with a diagnosis of asthma or COPD for at least one year were enrolled in the study. The frequency of ACO and the characteristics of the patients were evaluated in the asthma and COPD groups. Results: The study included 408 subjects (F/M= 205/203, mean age= 56.24 ± 11.85 years). The overall prevalence of ACO in both groups was 20.8% (n= 85). The frequency was higher in the COPD group than in the asthma group (n= 55; 33.3% vs. n= 22; 9.8%), respectively (p= 0.001). Patients with ACO had similarities to patients with COPD in terms of advanced age, sex, smoking, exposure to biomass during childhood, being born in rural areas, and radio-logic features. Characteristics such as a history of childhood asthma and allergic rhinitis, presence of chronic sinusitis, NSAID hypersensitivity, atopy, and high eosinophil counts were similar to those of patients with asthma (p< 0.001). The annual decline in FEV1 was more prominent in the ACO group (mean=-250 mL) than in the asthma (mean change=-60 mL) and COPD (mean change=-230 mL) groups (p= 0.003). Conclusion: This study showed that ACO was common among patients with asthma and COPD in tertiary care clinics in our country. ACO should be considered in patients with asthma and COPD who exhibit the abovementioned symptoms. © 2024 by Tuberculosis and Thorax.Item Elderly and aged asthma have different characteristics: results of a multicenter study(Turkiye Klinikleri, 2024) Damadoğlu E.; Öztürk Aktaş Ö.; Gemicioğlu B.; Yilmaz N.; Bozkuş F.; Ayhan V.; Kalpaklioğlu A.F.; Öner Erkekol F.; Havlucu Y.; Erel F.; Aydin Ö.; Ekici A.; Baççioğlu A.; Argun Bariş S.; Köycü Buhari G.; Ceyhan B.; Göksel Ö.; Köse M.; Dursun A.B.; Yildiz F.; Yorgancioğlu A.; Işik S.R.; Ediger D.; Oğuzülgen İ.K.; Demir A.U.; Karakaya G.; Kalyoncu A.F.Background/ aim: Characteristics of asthma in the elderly population is not well-known. The aim of the present study was to evaluate asthma in the elderly population, to compare disease characteristics between patients diagnosed <60 (aged asthma) and ≥60 (elderly asthma) years of age. Materials and methods: The study was a prospective, multicenter, cross-sectional type. A questionnaire was filled out to patients 60 years of age and over, that have been followed for asthma for at least 3 months. Asthma Control Test (ACT), eight-item Morisky Medication Adherence Scale (MMAS-8) was filled out, inhaler device technique was assessed. Results: A total of 399 patients were included from 17 tertiary care centers across the country. Mean age was 67.11 years and 331 (83%) were female. The age at asthma diagnosis was ≥60 in 146 (36.6%) patients. Patients diagnosed ≥60 years were older (p < 0.001), had higher education level (p < 0.001), more commonly had first-degree relative with asthma (p = 0.038), asthma related comorbidities (p = 0.009) and accompanying rhinitis/rhinosinusitis (p = 0.005), had better asthma control (p = 0.001), were using less controller medications (p = 0.014). Inhaler technique was correct in 37% of the patients with no difference in between the groups. Treatment compliance was better in elderly asthma patients (p < 0.001). In the multivariate logistic regression analysis, having well-controlled asthma (odds ratio = 1.61, CI = 1.04–2.51), and high medication adherence rate (odds ratio = 2.43, CI = 1.48–4.0) were associated with being in the elderly asthma group. Conclusion: The characteristics of asthma are different among patients aged 60 years and over which seems to be related to onset age of asthma. In our cohort, the elderly asthma patients had higher education level, and treatment adherence and asthma control was better. Patients diagnosed ≥60 years of age did not have more severe disease. © 2024, Turkiye Klinikleri. All rights reserved.